10-methyl spiro(4.5)dec-6-en-6-carboxylic acid has been researched along with Obesity in 1 studies
*Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY). [MeSH]
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alquicer, G; Balcaen, T; Bardova, K; Benova, A; Cajka, T; Dzubanova, M; Ferencakova, M; Funda, J; Horakova, O; Kerckhofs, G; Kopecky, J; Mracek, T; Pecinova, A; Prochazka, J; Rossmeisl, M; Spoutil, F; Tencerova, M; van Lenthe, GH; Willekens, W | 1 |
1 other study(ies) available for 10-methyl spiro(4.5)dec-6-en-6-carboxylic acid and Obesity
| Article | Year |
|---|---|
Novel thiazolidinedione analog reduces a negative impact on bone and mesenchymal stem cell properties in obese mice compared to classical thiazolidinediones.
Topics: Animals; Bone Marrow Stromal Antigen 2; Glucose; Glutamine; Humans; Hypoglycemic Agents; Insulin; Mesenchymal Stem Cells; Mice; Mice, Obese; Obesity; Pioglitazone; PPAR gamma; Spiro Compounds; Thiazolidinediones | 2022 |